Moderate-to-Severe Hot Flashes Persisting After Estrogen-Progestogen Therapy
This protocol addresses menopausal women with moderate-to-severe hot flashes and an intact uterus whose first-line hormonal management did not produce adequate vasomotor symptom relief. It defines the structured clinical step that follows.
Clinical scenario
Moderate to severe hot flashes (vasomotor symptoms) in a woman with an intact uterus and no contraindication to estrogen therapy, where first-line hormonal treatment has not achieved sufficient control of vasomotor symptoms.
Previous treatment — insufficient response
The prior line — estrogen-progestogen therapy (EPT) or the tissue-selective estrogen complex (TSEC) — was used to achieve adequate reduction of hot flashes and night sweats (vasomotor symptoms). That target was not met. This protocol represents the defined next clinical step.
Next-step approach (overview only)
When hormonal therapy has not provided sufficient vasomotor relief, a structured approach using non-hormonal prescription medications — including agents from the SSRI/SNRI class and gabapentinoids, among others — may be considered. The complete selection criteria, sequencing, and clinical specifics are contained in the full protocol.
References
- Moderate to severe hot flashes: MHT is the gold standard and best therapy for reduction of VMS (Tables 1-5), followed by non-hormonal prescription medications (Tables 6, 7) as a second choice.
- Women with a uterus can use either systemic estrogen combined with a progestogen (EPT) or the tissue-selective estrogen complex (conjugated equine estrogens and bazedoxifene).
- For those with contraindications to hormone therapy or a desire to avoid it, SSRI/SNRIs, gabapentinoids, or clonidine may reduce VMS in some women.
View source ↗